Compare Atlassian Corporation PLC (TEAM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs TG Therapeutics Inc — how do they compare? Atlassian Corporation PLC trades at $90.91 (market cap $23.67B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Atlassian Corporation PLC is far larger — about 2.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| TEAM | TGTX | |
|---|---|---|
Market Cap | $23.67B | $8.26B |
Sector | Technology | Health |
52-Week High | $203.00 | $59.06 |
52-Week Low | $57.15 | $26.39 |
Enterprise Value | $23.78B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $90.60, down 2.88% on the day, with a bullish technical signal from moving averages and strong analyst support (67% buy ratings). The company shows accelerating revenue growth, reaching $5.22B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven product enhancements and enterprise adoption momentum, with the Service Collection surpassing $1B in annual recurring revenue.
TEAM presents a growth investment case with a consensus price target of $114.54 (26% upside), supported by cloud momentum and AI integration. However, persistent net losses (-$256.69M in 2025) and high valuation multiples (P/S 3.96, P/B 26.93) pose risks amid competitive pressures and macroeconomic sensitivity in software spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
